Johnson & Johnson’s Phase 3 trial of its COVID-19 vaccine candidate has commenced in South Africa. The first South African ENSEMBLE participants were dosed last week. The study is also on-going in the United States, Brazil, Chile, Colombia and Argentina. Ludovic de Beaucoudrey, the Medical Affairs Director at Janssen South Africa joins CNBC Africa for more.